Tags:Science & TechUPSC
Source:Indian Express
Subject: Health, Science and Technology: Antimicrobial Resistance and Public Health Infrastructure|Target exams: UPSC
Key points for Prelims: ICMR, AMRSN, Escherichia coli, Carbapenems, Methicillin-resistant Staphylococcus aureus, Klebsiella pneumoniae
Mains syllabus mapping
- General Studies Paper 2: Health: issues relating to public health, diseases, and healthcare infrastructure; role of ICMR and other institutions
- General Studies Paper 3: Science and Technology: developments and their applications in health; biotechnology and antimicrobial research
Antimicrobial Resistance Surveillance and Research Network (ICMR AMRSN): quick facts
- Coordinating centre
- ICMR Headquarters, New Delhi
- Network structure
- 6 nodal centres in 4 tertiary care institutions and 16 regional centres
- Pathogen groups
- 6 groups: diarrhoeagenic bacteria, enteric fever pathogens, Enterobacteriaceae causing sepsis, Gram-negative non-fermenters, Gram-positives including MRSA, and fungi
Key facts for one-day exams
- ICMR published the AMRSN Annual Report 2025.
- The report examined 1,13,008 positive samples from 30 large specialised hospitals.
- The 34 smaller hospitals contributed 20,529 positive samples.
- Carbapenem resistance was 91.1% among tested A. baumannii samples.
- Methicillin resistance was 56.8% among tested Staphylococcus aureus samples.
ICMR AMRSN Annual Report 2025: why in the news?
The ICMR's AMRSN Annual Report 2025, released recently, documents a sharp decline in antibiotic effectiveness against common bacteria in hospital samples across India, including in smaller hospitals for the first time, raising concerns about treatment options for infections.
The Indian Council of Medical Research (ICMR) has warned that several common bacteria are no longer responding to antibiotics that doctors have used for years, according to its Antimicrobial Resistance Surveillance and Research Network (AMRSN) Annual Report 2025. The report, which examined 1,13,008 positive laboratory samples from 30 large specialised hospitals and 20,529 samples from 34 smaller secondary-care hospitals in 2025, found that Escherichia coli was the most commonly identified bacterium, accounting for 24.4 per cent of samples from large hospitals. The findings point to a worrying trend of declining antibiotic effectiveness across different levels of healthcare.
The report found that only 18.4 per cent of tested E. coli samples responded to cefotaxime and 24.7 per cent to ceftazidime, two commonly used antibiotics, while just 9 per cent responded to ciprofloxacin. Among tested Klebsiella pneumoniae samples, only 36.5 to 40.4 per cent responded to carbapenems, a group of powerful antibiotics, with even lower response in intensive-care unit samples. The report also found that 91.1 per cent of tested Acinetobacter baumannii samples showed resistance to carbapenems, and 56.8 per cent of tested Staphylococcus aureus samples were resistant to methicillin. For the first time, the report included separate findings on bloodstream infections among newborns, where Klebsiella pneumoniae was the most commonly identified bacterium, accounting for 25.1 per cent of tested samples.
Key features and how it works
- Hospital network: tertiary care hospitals track trends in the antimicrobial susceptibility profile of clinically important bacteria and fungi, limited to human health.iamrsn.icmr.org.in
- Nodal centres: each of the six pathogen groups has a nodal centre, for example AIIMS New Delhi for enteric fever pathogens, PGIMER Chandigarh for sepsis-causing Enterobacteriaceae and fungal infections, CMC Vellore for diarrhoeagenic bacteria and gram-negative non-fermenters, and JIPMER Puducherry for gram-positives including MRSA.iamrsn.icmr.org.in
- Regional centres: 16 regional labs from tertiary care hospitals send data on a fixed number of isolates for each pathogen group, following ICMR standard operating procedures for bacteriology and mycology.iamrsn.icmr.org.in
- Data system: ICMR runs a real-time web-based online AMR data entry system for collection, storage and analysis. Nodal centres validate data first.iamrsn.icmr.org.in
- Molecular studies: nodal centres exchange organisms for in-depth molecular studies of clonality and transmission of drug-resistant pathogens.iamrsn.icmr.org.in
Related Static GK and comparison
- Indian Council of Medical Research (ICMR): the apex body for biomedical research in India, funded through the Department of Health Research, Ministry of Health and Family Welfare; it was redesignated from the Indian Research Fund Association in 1949.
- The AMRSN portal includes links to AMR ICMR Data, SOPs and Antimicrobial Stewardship Programme (AMSP) pages.iamrsn.icmr.org.in
- Antimicrobial resistance (AMR): microbes evolve protection against antimicrobial drugs; MDR (multidrug-resistant) microbes are called superbugs; the WHO estimated that bacterial AMR directly caused 1.27 million deaths in 2019.
- WHO GLASS: the Global Antimicrobial Resistance and Use Surveillance System, launched on 22 October 2015 as the first global collaborative effort to standardise AMR surveillance.WHO
AMRSN vs WHO GLASS
| Basis | ICMR AMRSN | WHO GLASS |
|---|---|---|
| Launch year | 2013 | 22 October 2015 |
| Scope | Hospital-based surveillance of clinically important bacteria and fungi in India | Global standardised collection of AMR and antimicrobial use data, including national systems |
| Implementing body | ICMR, under Department of Health Research | World Health Organization |
| Pathogen focus | 6 pathogen groups aligned with the WHO priority pathogen list (2017) | Common bacterial infections in humans (GLASS-AMR), plus fungi and gonorrhoea modules |
Achievements
- The 2025 report covered hospitals of two levels, large specialised and secondary-care, and for the first time gave separate findings on newborn bloodstream infections.
- The network's pathogen groups align with the WHO priority pathogen list released in 2017.iamrsn.icmr.org.in
Challenges
- Resistance is high in the report: only 9% of tested E. coli samples responded to ciprofloxacin, and 91.1% of Acinetobacter baumannii samples were resistant to carbapenems.
- Data quality depends on consistent sampling across hospitals, so regional centres must follow the same SOPs.
- Surveillance covers hospital samples only, so resistance in community and animal settings is not captured.
Way forward
- Outcome monitoring: link annual resistance data to changes in prescribing and track whether resistance falls.
- Convergence with antimicrobial stewardship programmes and the One Health approach used by WHO GLASS.WHO
Antibiotic response in selected bacteria
| Bacterium | Antibiotic | Response |
|---|---|---|
| E. coli | Cefotaxime | 18.4% |
| E. coli | Ceftazidime | 24.7% |
| E. coli | Ciprofloxacin | 9% |
| Shigella flexneri | Ciprofloxacin | 7.5% |
| Shigella sonnei | Ciprofloxacin | 8.9% |
Key terms
- Antimicrobial resistance:
- Antimicrobial resistance is the ability of microorganisms to survive or grow despite medicines intended to act against them.
- Antibiotic susceptibility testing:
- Laboratory testing determines whether a bacterium is susceptible or resistant to particular antibiotics.
- Carbapenems:
- Carbapenems are a group of antibiotics used to treat serious bacterial infections, including some where other medicines fail.
- Antibiotic stewardship:
- Antibiotic stewardship is the careful and responsible use of antibiotics to improve treatment and limit resistance.
ICMR AMRSN Annual Report 2025: why it matters for exams
Exams: UPSC
Syllabus: Science and Technology: Microorganisms and antimicrobial resistance; Society: Public health and healthcare
Common mistake: Examiners may present 91.1% as carbapenem susceptibility rather than resistance: the figure is resistance among tested A. baumannii samples.
Mains practice questions
Question 1(GS-2 | 250 words | 15 marks)
Rising antimicrobial resistance is now visible even in smaller secondary-care hospitals in India, not only in large tertiary centres. Critically examine the factors behind this spread and evaluate the measures needed to contain it.
Answer outline
- Introduction: Open by noting that the ICMR AMRSN Annual Report 2025 found falling antibiotic effectiveness across both large specialised and smaller secondary-care hospitals, making resistance a system-wide rather than a tertiary-care problem.
- Body:
- Explain the surveillance findings: E. coli as the most common isolate, low response to cefotaxime, ceftazidime and ciprofloxacin, and high carbapenem resistance in Acinetobacter baumannii.
- Analyse drivers: indiscriminate or empirical antibiotic prescribing, self-medication and over-the-counter sales, weak infection prevention and hospital hygiene, and inadequate diagnostic laboratories in smaller hospitals.
- Discuss the significance of newborn bloodstream infections caused by Klebsiella pneumoniae, which highlights vulnerability in neonatal care and hospital-acquired infection control.
- Evaluate remedies: antimicrobial stewardship programmes, strengthening laboratory capacity and surveillance networks such as AMRSN, regulating sale of antibiotics, and the One Health approach linking human, animal and environmental health.
- Note the role of ICMR in generating data for evidence-based treatment guidelines and policy.
- Conclusion: Conclude that containing resistance requires coordinated stewardship, lab strengthening and public awareness across all tiers of care, with surveillance data used to guide prescribing and policy.
Question 2(GS-3 | 150 words | 10 marks)
Discuss the role of surveillance networks in generating evidence for public health policy, with reference to the findings of the ICMR AMRSN Annual Report 2025.
Answer outline
- Introduction: Open by stating that the AMRSN report, analysing over one lakh positive samples from large hospitals and thousands from secondary-care hospitals, shows how systematic surveillance turns clinical data into policy evidence.
- Body:
- Explain how AMRSN collects and analyses isolate-level data across multiple hospitals, enabling tracking of resistance trends over time.
- Cite findings that inform policy: declining response of E. coli and Klebsiella pneumoniae to key antibiotics, and the first-time inclusion of newborn bloodstream infections.
- Discuss how such data can guide empirical treatment guidelines, antibiotic policy, and targeting of infection control resources.
- Note limitations such as uneven laboratory capacity and the need to widen the network to more facilities.
- Conclusion: Conclude that sustained, well-resourced surveillance is essential for timely, evidence-based antimicrobial policy.
Stuck? Get it in one tap
Antibiotic resistance means bacteria can survive medicines used to treat them. ICMR hospital data show that several antibiotics work against fewer tested bacterial samples. Laboratory tests can help doctors choose a suitable medicine, while hygiene and careful antibiotic use help control the problem.
- Science and Technology: Microorganisms and antimicrobial resistance
- Society: Public health and healthcare
Related concepts: Antimicrobial resistance, Antibiotic susceptibility testing, Carbapenems, Antibiotic stewardship
Practice questions
Pick an answer, then read the explanation.
- Q1Easy
Which organisation publishes the Antimicrobial Resistance Surveillance and Research Network Annual Report 2025?
Explanation: The Indian Council of Medical Research publishes the AMRSN annual report. The network examines antimicrobial resistance using hospital laboratory data.
- Q2Hard
Consider the following statements about the AMRSN Annual Report 2025:
- 1.The report included data from 34 smaller secondary-care hospitals for the first time.
- 2.Klebsiella pneumoniae was the most commonly identified bacterium in tested newborn bloodstream samples.
- 3.A. baumannii showed 91.1% susceptibility to carbapenems.
Which of the statements given above are correct?
Explanation: Statements 1 and 2 are correct: smaller hospitals were newly included and Klebsiella pneumoniae led the newborn bloodstream findings. Statement 3 is incorrect because 91.1% refers to carbapenem resistance, not susceptibility.
- Q3Medium
What percentage of tested E. coli samples responded to ciprofloxacin in the AMRSN Annual Report 2025?
Explanation: Ciprofloxacin response was 9% among tested E. coli samples. The figures 18.4% and 24.7% correspond to cefotaxime and ceftazidime response, while 7.5% was the ciprofloxacin response for Shigella flexneri.
- Q4Medium
Why should hospitals use local resistance data when selecting antibiotics for bacterial infections?
Explanation: Bacterial profiles and resistance patterns vary across hospitals, so local data and laboratory testing can guide antibiotic selection. A uniform choice, routine carbapenem use or symptoms alone cannot account for these differences.
Frequently asked questions
1. What does the ICMR AMRSN Annual Report 2025 study?
The report examines antimicrobial resistance in microorganisms identified in hospital laboratory samples across India.
2. Which bacterium was most common in large hospitals in the AMRSN 2025 findings?
Escherichia coli accounted for 24.4% of samples from the large hospitals covered.
3. How many smaller hospitals were included in the AMRSN 2025 report?
The report included 34 smaller secondary-care hospitals, including 12 district hospitals.
4. Which bacterium was most common in tested newborn bloodstream samples?
Klebsiella pneumoniae accounted for 25.1% of tested samples from newborns aged 0-28 days.
All sources
Original18 November 2026 · Read story


